Severe hypercalcemia following denosumab treatment in a juvenile patient

Journal of Bone and Mineral Metabolism

Volumn 34, Issue 1, 2016, Pages 118-122

  Setsu, Nokitaka ^a   Kobayashi, Eisuke ^a   Asano, Naofumi ^a   Yasui, Naoko ^a   Kawamoto, Hiroshi ^a   Kawai, Akira ^a   Horiuchi, Keisuke ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Denosumab; Giant cell tumor of bone; Hypercalcemia; Pediatric

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCITRIOL; CALCIUM CARBONATE; COLECALCIFEROL; DENOSUMAB; ELCATONIN; PARATHYROID HORMONE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ALKALOSIS; ARTICLE; CALCIUM BLOOD LEVEL; CASE REPORT; CHILD; DEHYDRATION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; HORMONE BLOOD LEVEL; HUMAN; HYPERCALCEMIA; LOSS OF APPETITE; MALE; NAUSEA; OSTEOCLASTOMA; OSTEOLYSIS; PRIORITY JOURNAL; REBOUND; SCHOOL CHILD; SINUS BRADYCARDIA; TREATMENT OUTCOME; BONE NEOPLASMS; CHEMICALLY INDUCED;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; CHILD; DENOSUMAB; HUMANS; HYPERCALCEMIA; MALE;

EID: 84952874461     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-015-0677-z     Document Type: Article

References (9)

1. Athanasou NA, Bansal M, Forsyth R, Reid RP, Sapi Z (2013) Giant cell tumour of bone. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens FE (eds) World Health Organization classification of tumours of soft tissue and bone. IARC Press, Lyon, pp 321–324
2. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I (2013) Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 9:901–908
3. Kobayashi E, Setsu N (2015) Osteosclerosis induced by denosumab. Lancet 7;385:539
4. Fischer DC, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G, Haffner D (2012) Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem 6:546–553
5. Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, Reid IR, Vanderschueren D, Cosman F (2012) Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. J Bone Miner Res 5:963–974
6. Boyce AM, Chong WH, Yao J, Gafni RI, Kelly MH, Chamberlain CE, Bassim C, Cherman N, Ellsworth M, Kasa-Vubu JZ, Farley FA, Molinolo AA, Bhattacharyya N, Collins MT (2012) Denosumab treatment for fibrous dysplasia. J Bone Miner Res 7:1462–1470
7. Grasemann C, Schundeln MM, Hovel M, Schweiger B, Bergmann C, Herrmann R, Wieczorek D, Zabel B, Wieland R, Hauffa BP (2013) Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget’s disease. J Clin Endocrinol Metab 8:3121–3126
8. Gossai N, Hilgers MV, Polgreen LE, Greengard EG (2015) Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer (Epub ahead of print)
9. Papapoulos SE, Cremers SC (2007) Prolonged bisphosphonate release after treatment in children. N Engl J Med 10:1075–1076